Author

Y. Doering

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

C. Weber· 2 shared A. Bonnin-Marquez· 1 shared A. Goetz· 1 shared A. Gorter· 1 shared A. Jans· 1 shared B. Finan· 1 shared C. Lin· 1 shared E. A. L. Biessen· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

C. Weber

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles.

L. Peters, L. Rakateli, R. Huchzermeier, A. Bonnin-Marquez, S. L. Maas, C. Lin, A. Jans, Y. Geng, A. Gorter, M. Gijbels, S. Rensen, P. Olinga, T. Hendrikx, M. Krawczyk, M. Brisbois, , E. P. C. van der Vorst

This paper shows that miR-26b deficiency worsens MASH in mice, and that miR-26b mimic-loaded LNPs can reverse these effects.

bioRxiv · Feb 18, 2024Pathology

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight in obese mice

S. Sachs, A. Goetz, B. Finan, R. D. DiMarchi, Y. Doering, C. Weber, M. Tschoep, T. D. Mueller, S. M. Hofmann

This study shows that GIP receptor agonism reduces dyslipidemia and atherosclerosis in obese mice without affecting body weight.

bioRxiv · Mar 15, 2022 · PreprintPharmacology & Toxicology